Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer

Journal of Clinical Oncology

Volumn 32, Issue 27, 2014, Pages 2935-2937

  Loi, Sherene ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ANTHRACYCLINE; BRCA1 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TUMOR MARKER;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; HAZARD RATIO; HUMAN; IMMUNE RESPONSE; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; FEMALE; PATHOLOGY;

FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84907210556     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.7677     Document Type: Review

References (28)

1. Adams S, Gray RJ, Demaria S, et al: Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959-2966, 2014
2. Dieci MV, Criscitiello C, Goubar A, et al: Prognostic value of tumorinfiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study. Ann Oncol 25:611-618, 2014
3. Loi S, Michiels S, Salgado R, et al: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit: Results from the FinHER trial. Ann Oncol [epub ahead of print on April 29, 2014]
4. Loi S, Sirtaine N, Piette F, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31:860-867, 2013
5. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
6. Marginean F, Rakha EA, Ho BC, et al: Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. Mod Pathol 23:1357-1363, 2010
7. Denkert C, Loibl S, Noske A, et al: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105-113, 2010
8. Mahmoud SM, Paish EC, Powe DG, et al: Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949-1955, 2011
9. Gu-Trantien C, Loi S, Garaud S, et al: CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 123:2873-2892, 2013
10. Desmedt C, Haibe-Kains B, Wirapati P, et al: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165, 2008
11. Kreike B, van Kouwenhove M, Horlings H, et al: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9:R65, 2007
12. Lehmann BD, Bauer JA, Chen X, et al: Identification of human triplenegative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767, 2011
13. Teschendorff AE, Miremadi A, Pinder SE, et al: An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8:R157, 2007
14. Loi S, Michiels S, Salgado R, et al: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2013 (abstr S1-05)
15. Schalper KA, Velcheti V, Carvajal D, et al: In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 20:2773-2782, 2014
16. Velcheti V, Schalper KA, Carvajal DE, et al: Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 94:107-116, 2014
17. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
18. Brown SD, Warren RL, Gibb EA, et al: Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24:743-750, 2014
19. Lawrence MS, Stojanov P, Polak P, et al: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 11:214-218, 2013
20. Ladoire S, Mignot G, Dabakuyo S, et al: In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 224:389-400, 2011
21. Ladoire S, Arnould L, Apetoh L, et al: Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 14:2413-2420, 2008
22. Verbrugge I, Hagekyriakou J, Sharp LL, et al: Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 72:3163-3174, 2012
23. Loi S, Pommey S, Haibe-Kains B, et al: CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A 110:11091-11096, 2013
24. Beavis PA, Divisekera U, Paget C, et al: Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A 110:14711-14716, 2013
25. Matsushita H, Vesely MD, Koboldt DC, et al: Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482: 400-404, 2012
26. John LB, Devaud C, Duong CP, et al: Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 19:5636-5646, 2013
27. Ochsenbein AF, Klenerman P, Karrer U, et al: Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 96:2233-2238, 1999
28. Bidwell BN, Slaney CY, Withana NP, et al: Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 18:1224-1231, 2012